Podchaser Logo
Home
160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

Released Thursday, 19th July 2018
Good episode? Give it some love!
160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

160 - darunavir single tablet; pain relief study; Tau modifier gets orphan drug designation; IND for CARMA platform; CAM2038 for opioid use disorder; FDA's speedy oncology review pilot; empowering nonprescription drugs

Thursday, 19th July 2018
Good episode? Give it some love!
Rate Episode

July 19, 2018 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

0:45 Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-symtuza-dcftaf-the-first-and-only-complete-darunavir-based-single-tablet-regimen-for-the-treatment-of-hiv-1-infection-300682550.html 

3:00 PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study https://www.prnewswire.com/news-releases/painreform-gets-fda-approval-for-phase-iii-post-operative-pain-relief-study-300682836.html

4:08 Asceneuron's Tau Modifier ASN120290 Receives Orphan Drug Designation for Progressive Supranuclear Palsy From the FDA

https://www.prnewswire.com/news-releases/asceneuron-s-tau-modifier-asn120290-receives-orphan-drug-designation-for-progressive-supranuclear-palsy-from-the-fda-859244062.html

6:20 MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

https://www.prnewswire.com/news-releases/maxcyte-receives-us-fda-investigational-new-drug-clearance-for-first-clinical-program-300681147.html

8:17 Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

https://www.prnewswire.com/news-releases/camurus-announces-pdufa-date-for-cam2038-for-the-treatment-of-opioid-use-disorder-300681160.html

9:33 FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613801.htm

12:16 Statement from FDA Commissioner Scott Gottlieb, M.D. on new efforts to empower consumers by advancing access to nonprescription drugs

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613692.htm

Just to let you know, I have a couple of new courses on Udemy. If you type in “Emma Nichols”, you’ll pull up my courses. The latest ones are Cancer Biology 101, How to Read and Interpret a Scientific Paper, and Freelance Medical Writing as a Career Choice. To check those out, just go to Udemy.com (Udemy.com) and type in “Emma Nichols” to pull them up.

 

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features